From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(7), P. 2486 - 2486

Published: April 5, 2025

Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a contributor to chronic kidney (CKD), yet its impact remains underappreciated in clinical practice. Recent studies reveal strong association between NAFLD and CKD progression, with evidence linking hepatic dysfunction renal impairment through metabolic inflammatory pathways. not only increases the risk of but also accelerates leading worse cardiovascular outcomes higher mortality, particularly patients advanced fibrosis. Despite this growing evidence, often goes undiagnosed routine evaluation rarely integrated into nephrology care. Emerging diagnostic tools, including noninvasive biomarkers imaging techniques, offer potential for earlier detection, their implementation inconsistent. Although lifestyle modifications remain foundation treatment, pharmacotherapeutic strategies, SGLT2 inhibitors GLP-1 receptor agonists, have demonstrated mitigating both impairment. Recognizing interplay essential improving patient outcomes. A multidisciplinary approach, integrating hepatology expertise, crucial refining screening optimizing reducing long-term burden these coexisting conditions.

Language: Английский

Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(47), P. 5070 - 5075

Published: Nov. 25, 2024

In this article, we comment on the article by Qu and Li, focusing specifically non-invasive diagnostic approaches for metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is most common chronic in children. Nearly half of pediatric cases progress to steatohepatitis at diagnosis, often with comorbidities like renal disease, hypertension, type 2 diabetes, mental health disorders. Early diagnosis continuous intervention are crucial managing "silent organ" disease. Screening recommended children aged nine older obesity. Liver biopsy remains gold standard; however, due its invasiveness, methods - biomarkers, anthropometric algorithms, serum tests, imaging increasingly vital. This editorial provides an overview current or fibrosis.

Language: Английский

MASLD as a Multisystemic Disease

Published: Jan. 1, 2024

Language: Английский